Alogliptin With Metformin
Recommended EndocrinologyAuthority RequiredSecond-line line
Type 2 diabetes mellitus in patients whose HbA1c is greater than 7% despite treatment with metformin, without requiring prior intolerance or contraindication to metformin and sulfonylurea combination.
1
Submissions
1 resub
2013–13
On the record
—
ICER range
Cost-min
Cost basis
Decision on record
- Meeting Nov 2013 Recommended alogliptin 12.5mg + metformin 500mg, alogliptin 12.5mg + metformin 850mg, alogliptin 12.5mg + metformin 1000mg, tablet Nesina Met® Takeda Pharmaceuticals Australia Pty Ltd Major submission Type 2 diabetes Authority Required (STREAMLINED) listing for the treatment of type 2 diabetes in a patient whos
Access path
- Nov 2013Recommended · restricted
vs alogliptin plus metformin individual tablets
- PBS listing · Authority Required
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis; no ICER calculated by design
The PBAC considered that the cost-effectiveness of the aloglitpin/metformin FDC would be acceptable if it were cost-minimised against the ex-manufacturer prices corresponding to the component prices for aloglitpin and metformin. PBAC · 2013
Cost-effectiveness accepted
Decision context
PopulationAdult patients (≥18 years) with type 2 diabetes mellitus whose HbA1c is greater than 7% despite treatment with metformin alone, where a dipeptidyl peptidase 4 inhibitor is appropriate, and where metformin and sulfonylurea combination is contraindicated or not tolerated.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2013 | Recommended · restricted | alogliptin plus metformin individual tablets | — | RCT · Surrogate |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to second-line use after metformin failure with HbA1c >7%, excluding sulfonylurea-eligible patients.